Mumbai, Maharashtra, India, Friday, January 18, 2013 — (Business Wire India) — The Board of Directors of Unichem Laboratories Ltd at their meeting held on January 18, 2013 approved the Third Quarter (Q3) Unaudited Results for FY 2012-13
The Company recorded a total income of Rs. 232.57 Crores for the quarter ended December 31, 2012 as against Rs. 222.62 Crores in the corresponding quarter of the previous year recording an increase of over 4%. The Total Income for Nine months ended December 31, 2012 increased by 25% as compared to corresponding nine months.
Profit after tax for the current quarter stood at Rs. 30.34 Crores as against Rs. 24.46 crores recorded in the corresponding quarter of the previous year showing an increase of 24%. Profit after tax for nine months ended December 31, 2012 increased by 66% as compared to corresponding nine months.
About Unichem Laboratories Limited
Unichem Laboratories Limited is an International, integrated, speciality pharmaceutical Company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the Company is a leaded in niche areas of cardiology, neurology and other orthopadics and anti-infectives. The Company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.
More information about the Company can be found at www.unichemlabs.com.
BSE: 506690; NSE: UNICHEMLAB; Reuters: UNLB.BO; Bloomberg: UN@IN
CONTACT DETAILS
Mr. M Gundu Rao, Unichem Laboratories Limited, +91 9820228944 / +91 (22) 66888380, gundurao@unichemlabs.com
Mr. Rakesh Parikh, Unichem Laboratories Limited, +91 9892925555 / +91 (22) 66888414, rparikh@unichemlabs.com
Mr. K Subharaman, Unichem Laboratories Limited, +91 9833031121 / +91 (22) 66888404, subharamank@unichemlabs.com
